How Cambridge Biotherapies Cut Health Costs ~50% Without Losing a Single Doctor — Then Kept Saving

The situation: a small specialty practice on a plan nobody had pressure-tested

Cambridge Biotherapies first set up health coverage in 2017 on a Blue Cross Blue Shield plan — but the plan decision was being driven by the office administrator, not optimized for the practice or its people. For a small, high-utilization specialty group, that’s an expensive way to buy insurance: nobody is pressure-testing the renewal, and the cost just rides whatever the incumbent quotes.

That changed when the administrator moved on and Chrystin Comeau stepped into clinic operations. She wanted the benefits actually managed — and brought Benefitra in to do it. The brief was specific: cut the cost, but don’t make employees pay more at the deductible and don’t take away their doctors.

Stage one: BCBS → MGB — ~50% lower, same deductibles, same doctors

The first move wasn’t a cheaper, thinner plan — it was a smarter placement. Benefitra moved the group from Blue Cross to a Mass General Brigham (MGB) plan that delivered roughly 50% lower health cost while holding the deductible and keeping the same doctor network. No trade-down — the same access, for about half the spend. As Comeau put it, the savings even "enabled us to add additional, valuable benefits."

The ~50% is Cambridge Biotherapies’ own stated figure for the BCBS→MGB move.

Stage two: MGB → a Taft-Hartley plan — the relationship kept finding savings

Most brokers would have stopped at a 50% win. Benefitra didn’t. As the relationship continued, they moved the benefits again — this time into a Taft-Hartley plan that pools a small group’s risk against a much larger base, squeezing out additional savings on top of the MGB plan. This is the difference between a one-time shopping exercise and an advisor who re-optimizes the structure as better options appear.

The honest trade-offs of the Taft-Hartley move

The second move buys its extra savings with a tighter benefit definition, and Benefitra put that on the table before the practice signed. Versus a top-tier fully-insured plan, the Taft-Hartley plan carries real carve-outs: no out-of-network benefit, no bariatric surgery, IVF capped, and GLP-1 medications not covered for weight loss (diabetes use only), among others. For a group whose utilization sits squarely in in-network specialty and primary care, the trade was worth it — which is exactly why it’s the right call here and not a blanket recommendation.

Outcome: about half the cost, the same care, and a relationship since 2017

Cambridge Biotherapies cut its health spend by roughly half on the carrier move alone — without raising what employees pay or taking away their doctors — then trimmed it further with the Taft-Hartley structure, and reinvested the savings into more benefits rather than fewer.

~50% lower (BCBS→MGB) · more on top (Taft-Hartley) · same doctors · client since 2017

And the strongest evidence the advice keeps working isn’t any single percentage — it’s that a practice that scrutinizes every operating dollar has trusted Benefitra with its benefits for nearly a decade, renewing year after year. When the people closest to the numbers keep coming back, that’s the audit that counts.